Complement Factor I Activity Assay

Creative Biolabs provides customized complement Factor I activity assay services to help researchers evaluate the regulatory function of Complement Factor I (CFI), characterize CFI-dependent cleavage of C3b and C4b, investigate cofactor-mediated complement control, and support the development of complement-targeted therapeutics.

Submit Your Request Now

Download our service brochure

Inquiry

Overview of CFI Activity Assay

Complement activation is designed to rapidly mark pathogens, immune complexes, damaged cells, and abnormal surfaces for elimination. However, because complement amplification can proceed quickly once C3b deposition begins, the system requires tightly coordinated regulatory mechanisms. CFI is one of the most important proteolytic regulators in this process. By cleaving C3b and C4b into inactive or further-degraded fragments, CFI helps limit convertase assembly, restrain alternative pathway amplification, and protect host tissues from uncontrolled complement-mediated damage.

Unlike many enzymes that act independently on a soluble substrate, Factor I is strongly cofactor dependent. This makes Factor I activity testing more complex but also more informative. A well-designed assay should consider not only the enzyme and substrate, but also the cofactor, the reaction matrix, the surface context, the detection method, and the biological question. For example, an assay built around CFI and Factor H may be useful for alternative pathway regulation, while an assay using C4b-binding protein may be more relevant for classical or lectin pathway control. A cell-surface assay involving CD46 or CR1 may better represent membrane-associated complement regulation.

Factor I functional testing is valuable in several major research areas:

Complement therapeutic development - to evaluate recombinant regulators, complement inhibitory biologics, engineered proteins, antibodies, peptides, small molecules, and gene therapy strategies.
Disease mechanism studies - to investigate altered complement regulation in atypical hemolytic uremic syndrome, C3 glomerulopathy, age-related macular degeneration, autoimmune disorders, inflammatory diseases, and complement-related susceptibility phenotypes.
Variant and mutation analysis - to compare activity of wild-type CFI with disease-associated or engineered variants.
Biologics characterization - to assess whether therapeutic antibodies, Fc-engineered molecules, nanoparticles, or biomaterials alter CFI-dependent complement regulation.
Cofactor dependency evaluation - to determine whether altered activity is caused by CFI itself, impaired cofactor binding, substrate availability, or interference within a complement regulatory complex.
Safety and mechanism-of-action studies - to identify unintended complement activation or insufficient complement control during drug development.

Creative Biolabs provides modular CFI activity assay design, allowing clients to select purified-protein, serum-based, cell-based, and customized formats according to the project stage and required depth of mechanistic interpretation.

Great Minds Choose Creative Biolabs

Partner with Us

Our CFI Activity Assay Platform

Creative Biolabs has established a comprehensive assay development platform for analyzing CFI activity across different biological contexts. Our platform can be configured to measure direct CFI-mediated cleavage, cofactor-assisted regulation, inhibition or enhancement of Factor I activity, and downstream effects on complement activation.

Purified-Protein CFI Activity Assay

The purified-protein assay format is suitable for dissecting the direct biochemical activity of CFI under controlled conditions. In this format, recombinant or purified CFI is incubated with defined substrates such as C3b or C4b in the presence of a selected cofactor. Reaction products are then detected using immunoblotting, ELISA-based approaches, capillary electrophoresis, mass spectrometry-compatible workflows, or other customized readout methods.

C3b Cleavage Assay

Creative Biolabs can design C3b cleavage assays using soluble C3b, surface-bound C3b, serum-derived components, or reconstituted systems. Readouts can be qualitative, semi-quantitative, or quantitative depending on project needs. For early-stage screening, a robust endpoint format may be sufficient. For lead characterization or mechanistic studies, kinetic and dose-response formats may be recommended.

C4b Cleavage Assay

Creative Biolabs can establish C4b cleavage assays with C4b-binding protein, CR1, CD46, or other applicable cofactors, depending on the biological question. The assay may be performed as a standalone biochemical study or incorporated into a broader complement pathway profiling package.

Cofactor-Dependent CFI Activity Assay

This format helps determine whether reduced activity is caused by impaired CFI catalytic function, abnormal substrate recognition, altered cofactor binding, or disrupted assembly of the substrate-cofactor-enzyme complex. For drug development programs, cofactor-dependent assays can also reveal whether a candidate molecule blocks or enhances a specific regulatory route.

Serum-Based Factor I Functional Assay

These assays can help determine whether a test article restores, suppresses, or dysregulates complement control in a biologically relevant environment. Depending on the project, downstream readouts may include C3b deposition, iC3b generation, C3a/C5a production, C5b-9 formation, hemolytic activity, or pathway-specific complement activation.

Cell-Based Complement Regulation Assay

Cell-surface complement regulation is highly relevant for host-cell protection, therapeutic antibody evaluation, engineered cell studies, biomaterial compatibility, and disease modeling. Creative Biolabs can develop cell-based assay systems to evaluate how Factor I-mediated regulation controls complement deposition and downstream activity on cell surfaces.

Discuss Your Needs

Service Options

Creative Biolabs offers multiple service options that can be selected individually or combined into an integrated CFI activity testing program.

Standard CFI Activity Testing

CFI Variant Functional Analysis

CFI Inhibitor or Enhancer Screening

Cofactor Interaction and Dependency Studies

Workflow of CFI Activity Assay

Complement FI assay. (Creative Biolabs Original) Fig. 1 CFH Western blotting workflow (left) and CFH ELISA workflow (right).

Design Your Workflow

Recommended Study Designs

Creative Biolabs can tailor study design to the specific research goal. Common study designs include the following.

Recombinant CFI Activity Confirmation

This design is suitable for confirming whether a recombinant CFI product is functionally active. The assay usually includes defined C3b or C4b substrate, a suitable cofactor, positive control CFI, negative control without enzyme, and optional dose-response testing.

Inhibitor Screening and Ranking

This design evaluates whether test articles reduce CFI-mediated cleavage. Compounds can be screened at a fixed concentration and then followed by dose-response testing for selected hits.

CFI Activity Rescue Study

This design is useful when depleted serum, deficient serum, or impaired complement regulation models are reconstituted with recombinant CFI. The assay can determine whether the added CFI restores regulatory function.

Cell-Surface Regulation Study

This design examines whether CFI-mediated regulation limits complement deposition or cytotoxicity on cells. It is useful for evaluating membrane regulators, antibody-opsonized targets, engineered cells, or complement-sensitive disease models.

Applications of CFI Activity Assay

Application	Description
Complement Drug Discovery	CFI activity assays can support the development of drugs that restore complement regulation, suppress excessive activation, or modulate complement amplification. Assays can be used for hit screening, lead optimization, mechanism-of-action studies, and candidate comparison.
Recombinant Complement Regulator Development	Recombinant CFI, engineered CFI variants, fusion proteins, and cofactor-based regulators require functional validation. Creative Biolabs can help determine whether engineered molecules retain or improve the desired regulatory activity.
Atypical Hemolytic Uremic Syndrome Research	Complement regulatory dysfunction is closely associated with atypical hemolytic uremic syndrome. CFI activity testing may help characterize functional defects, evaluate variants, and explore regulatory restoration strategies.
C3 Glomerulopathy and Renal Disease Research	Alternative pathway dysregulation is central to several complement-mediated renal disorders. CFI assays can be used to examine impaired C3b inactivation, serum-based complement overactivation, and response to complement-modulating candidates.
Age-Related Macular Degeneration Research	Complement regulatory genes, including CFI and other alternative pathway regulators, are relevant to AMD research. CFI activity assays can support the study of variant function, complement regulation, and therapeutic strategies aimed at restoring local complement control.
Autoimmune and Inflammatory Disease Studies	In autoimmune and inflammatory settings, complement activation may contribute to tissue injury, immune complex handling, and inflammatory amplification. CFI activity evaluation can help clarify whether insufficient regulation contributes to disease mechanisms.
Biologics and Antibody Safety Assessment	Therapeutic antibodies, Fc-engineered molecules, and cell-binding biologics may alter complement activation on target cells. CFI-related assays can be included in broader complement safety and mechanism studies.
Biomaterial and Nanomedicine Evaluation	Nanoparticles, delivery vehicles, and biomaterials may interact with complement proteins. CFI activity testing can help assess whether complement regulation is preserved or disrupted on artificial surfaces.

Design Your Customization

Case Studies

Case 1

Functional evaluation of CFI variants by immunoassays and SDS-PAGE

SDS-PAGE was applied to evaluate FI-mediated cleavage of the C3b α'-chain in the fluid phase in the presence of co-factors FH and sCR1. The eight recombinantly expressed FI-variants and the recombinantly expressed wild-type FI were evaluated in parallel to FI purified from human plasma. With FH as a co-factor, most FI mutants showed attenuated C3b degradation in comparison to both the recombinantly expressed wild type and the FI purified from plasma.

Evaluation of FI recombinant proteins. (OA Literature) Fig. 2 Functional analysis of recombinant FI proteins with SDS-PAGE.^1,2

References

Gerogianni, Alexandra, et al. "Functional evaluation of complement factor I variants by immunoassays and SDS-PAGE." Frontiers in Immunology 14 (2023): 1279612. https://doi.org/10.3389/fimmu.2023.1279612
Distributed under Open Access license CC BY 4.0, without modification.

What Our Clients Say

"Our program involved several recombinant CFI constructs, and simple concentration measurement was not enough to determine whether the proteins were functionally comparable. Creative Biolabs designed a C3b cleavage assay with Factor H as the cofactor and included time-course and dose-response conditions. The results helped us identify which constructs retained strong regulatory activity and which showed partial loss of function despite acceptable expression levels."

— Principal Scientist, Complement Therapeutics Company

"We were investigating CFI variants associated with complement-mediated renal disease and needed to know whether the functional defect was related to C3b cleavage, C4b cleavage, or cofactor dependency. Creative Biolabs developed a comparative assay panel using different cofactors and substrates. The study showed that one variant had reduced activity only under specific cofactor conditions, which would have been missed in a single-format assay."

— Translational Research Lead, Renal Disease Research Group

"We initially requested a purified-protein Factor I activity assay, but Creative Biolabs recommended adding a serum-based reconstitution format because our candidate was intended to restore complement regulation in a complex biological matrix. That recommendation was very valuable. The purified assay confirmed direct CFI-related activity, while the serum-based data showed how the same molecule affected downstream complement activation. The combination gave us a stronger functional package for candidate evaluation."

— Director of Preclinical Biology, Biopharmaceutical Company

"Our therapeutic antibody was not designed to target Factor I directly, but we were concerned that Fc-mediated complement engagement could interfere with regulatory balance on target cells. Creative Biolabs established a cell-based complement regulation assay and monitored surface C3 fragment deposition and terminal complement complex formation."

— Senior Scientist, Antibody Engineering Team

Frequently Asked Questions

What substrates can be used in a Factor I activity assay?

The most common substrates are C3b and C4b. C3b cleavage is especially relevant to alternative pathway regulation because inactivation of C3b limits amplification and convertase formation. C4b cleavage is relevant to classical and lectin pathway regulation. Depending on the project, assays may focus on C3b alone, C4b alone, or both substrates. The substrate choice should reflect the pathway of interest, disease context, therapeutic mechanism, and cofactor system being evaluated.

Which cofactor should I choose for my assay?

The best cofactor depends on the biological question. Factor H is often selected for studies focused on alternative pathway regulation and C3b inactivation. C4b-binding protein is commonly used for C4b regulation in classical and lectin pathway contexts. CD46 and CR1 may be more relevant for cell-surface complement regulation. If the project involves disease-associated variants, engineered cofactors, or therapeutic candidates, a comparative cofactor panel may be recommended to determine whether the observed effect is cofactor-specific.

Can CFI variants associated with disease be tested?

Yes. Creative Biolabs can compare wild-type CFI with disease-associated or engineered variants under matched assay conditions. This may include C3b cleavage, C4b cleavage, cofactor dependency, serum reconstitution, dose-response behavior, stability-related activity, and downstream complement regulation. Such testing can help determine whether a variant shows loss of function, partial function, cofactor-specific impairment, substrate-specific impairment, or near-normal activity under the selected conditions.

What types of test articles can be evaluated?

Creative Biolabs can evaluate a wide range of test articles, including recombinant CFI, CFI variants, engineered complement regulators, antibodies, small molecules, peptides, aptamers, fusion proteins, Fc-engineered biologics, gene therapy-related products, nanoparticles, biomaterials, serum samples, cell culture supernatants, and client-provided experimental compounds. Feasibility depends on sample format, concentration, stability, matrix compatibility, and assay readout.

Can the assay be quantitative?

Yes. Depending on the detection method and assay format, CFI activity assays can be developed as qualitative, semi-quantitative, or quantitative assays. Quantitative formats may include standard curves, dose-response curves, kinetic analysis, relative activity calculations, percent inhibition, percent enhancement, or normalized substrate conversion. For discovery-stage projects, relative activity may be sufficient, while later-stage programs may require more rigorous quantification and assay performance evaluation.